Erik Sirulnick, MD
Clinical Cardiac Electrophysiology · Las Vegas, NVNPI 1467408005
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $33,983 of the $43,594 with a category attached, or 78.0%. 19 manufacturers reported payments, led by Abbott at 32.7% of the total. Among clinical cardiac electrophysiology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $109.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$14K
- Medtronic$9K
- Biosense Webster, Inc.$5K
- Boston Scientific$4K
- E.r. Squibb & Sons, L.L.C.$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- plus $5K from 13 others
Across 4 payments — averaging $2676.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Atricure, Inc.$7K
- E.r. Squibb & Sons, L.L.C.$4K
What the payments were for
- Speaking & faculty fees$4,27510%
- Travel & lodging$5,33612%
- Food & beverage$33,98378%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 97 | $14,271 |
| Medtronic(2 entities) | 100 | $9,208 |
| Biosense Webster, Inc. | 52 | $5,199 |
| Boston Scientific | 49 | $4,044 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,245 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $2,439 |
| Cardiva Medical, Inc. | 47 | $1,070 |
| Philips North America LLC | 9 | $965 |
| Impulse Dynamics (USA) Inc. | 5 | $704 |
| Kowa Pharmaceuticals America, Inc. | 5 | $592 |
| Cvrx, Inc. | 3 | $561 |
| Biotronik Inc. | 3 | $401 |
| Abiomed | 2 | $277 |
| Edwards Lifesciences | 1 | $166 |
| Esperion Therapeutics, Inc. | 2 | $152 |
| Akcea Therapeutics, Inc. | 1 | $145 |
| Pfizer | 1 | $124 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$4,392
- ELIQUIS$2,995
- Carto 3$2,905
- Farapulse$1,997
- Micra$1,724
- LifeVest$1,618
- ENSITE$1,565
- OPTIMIZER$1,372
- Confirm Rx$1,320
- VISITAG SURPOINT External Processing Unit$875
- Carto 3 System$729
- Attain$727
- Soundstar$633
- Ensite Cardiac Mapping System$594
- Claria MRI$563
- Barostim Neo System$561
- (9520) IGT Devices Undivided$518
- PulseSelect$502
- EnSite Precision Cardiac Mapping System$501
- NUVISION ICE CATHETER$496
How this compares
$43,594 in reported general payments places this provider in the 90th percentile of 20 clinical cardiac electrophysiology providers in Nevada.
See all clinical cardiac electrophysiology providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 565 | $691,840 |
| XareltoRivaroxaban | 74 | $103,777 |
| JardianceEmpagliflozin | 45 | $53,979 |
| MultaqDronedarone Hcl | 25 | $50,027 |
| Repatha SyringeEvolocumab | 44 | $38,500 |
| EntrestoSacubitril/Valsartan | 24 | $33,986 |
| Repatha SureclickEvolocumab | 21 | $17,517 |
| Dofetilide | 31 | $15,859 |
| Praluent PenAlirocumab | 16 | $14,580 |
| Amiodarone Hcl | 63 | $4,877 |
| Flecainide Acetate | 151 | $4,560 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $4,493 |
| Diltiazem 12hr ErDiltiazem Hcl | 14 | $4,372 |
| SotalolSotalol Hcl | 300 | $3,832 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 59 | $3,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $124 | $691,840565 claims |
| Sanofi-aventis U.S. LLCMultaq | $16 | $50,02725 claims |
| NovartisEntresto | $15 | $33,98624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 clinical cardiac electrophysiology providers in Nevada.
Other clinical cardiac electrophysiology in Las Vegas
- Claudio BonomettiLas Vegas$89K
- Niuton KoideLas Vegas$34K
- David NavratilLas Vegas$29K
- Dhiraj NarulaLas Vegas$14K
- Santosh RaneLas Vegas$11K
- Gaston VergaraLas Vegas$11K
- Subhasree PanchangamLas Vegas$4K
- Khawaja BaigLas Vegas$3K
- Daejoon AnhHenderson$33K
- Jeffrey TurnerCarson City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.